Stock TECH BIO-TECHNE CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Company Bio-Techne Corporation

Equities

TECH

US09073M1045

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-23 pm EDT 		5-day change 1st Jan Change
63.69 USD +1.42% Intraday chart for Bio-Techne Corporation -0.50% -17.46%
Apr. 23 Bio-Techne Says It Filed Patent Infringement Lawsuit Against Molecular Instruments in Europe MT
Apr. 18 Deutsche Bank Adjusts Bio-Techne Price Target to $82 From $85 MT

Business Summary

Bio-Techne Corporation specializes in the manufacture and marketing of products used in life science research. The group offers reagents and diagnostic tools for researchers, doctors, laboratories, pharmaceutical and biotechnology companies, etc. Net sales break down by family of products as follows:

- biological and chemical reagents and analysis tools (74.3%): proteins, antibodies, molecules, culture serums, tools for cell work, tools for the study of proteins, immunoassay tools, etc.;

- diagnostic and genomics products (25.7%): reagents and products used in blood analysis, nucleic acid analysis, tissue biopsy, gene analysis, cancer and genetic carrier screening, etc.

Net sales are distributed geographically as follows: the United States (56.5%), the United Kingdom (4.4%), Europe/Middle East/Africa (19.4%), China (10%), Asia/Pacific (6.4%), and other (3.3%).

Number of employees: 3,050

Sales per Business

USD in Million2022Weight2023Weight Delta
Protein Sciences
74.4 %
832 75.3 % 846 74.4 % +1.61%
Diagnostics and Genomics
25.7 %
275 24.9 % 293 25.7 % +6.46%
Intersegment
-0.1 %
-2 -0.1 % -2 -0.1 % +5.92%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
56.5 %
614 55.5 % 642 56.5 % +4.62%
EMEA, excluding United Kingdom
19.4 %
219 19.8 % 220 19.4 % +0.54%
Greater China
10.0 %
112 10.2 % 114 10.0 % +1.27%
APAC, excluding Greater China
6.4 %
76 6.9 % 73 6.4 % -3.87%
United Kingdom
4.4 %
49 4.4 % 49 4.4 % +1.69%
Rest of World
3.3 %
35 3.2 % 37 3.3 % +6.44%

Managers

Managers TitleAgeSince
Kim Kelderman CEO
 Chief Executive Officer 57 18-04-29
James Hippel DFI
 Director of Finance/CFO 53 14-03-31
Matthew McManus COO
 Chief Operating Officer 55 Jan. 07
David Clair IRC
 Investor Relations Contact - -
Shane Bohnen LAW
 General Counsel 49 19-03-02
Qi Cheng PRN
 Corporate Officer/Principal - 21-07-26
Brenda Everson HRO
 Human Resources Officer - 22-01-09
William Geist PRN
 Corporate Officer/Principal 55 22-01-02
Robert Gavin PRN
 Corporate Officer/Principal 56 14-11-24

Members of the board

Members of the board TitleAgeSince
Robert Baumgartner CHM
 Chairman 68 02-12-31
Randolph Steer BRD
 Director/Board Member 74 89-12-31
Joseph Keegan BRD
 Director/Board Member 71 17-10-25
John Higgins BRD
 Director/Board Member 54 09-05-18
Kim Kelderman CEO
 Chief Executive Officer 57 18-04-29
Roeland Nusse BRD
 Director/Board Member 74 10-05-25
Julie Bushman BRD
 Director/Board Member 63 20-07-30
Rupert Vessey BRD
 Director/Board Member 59 19-06-25
Alpna Seth BRD
 Director/Board Member 60 17-10-25

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 157,191,685 155,658,446 ( 99.02 %) 0 99.02 %

Shareholders

NameEquities%Valuation
Vanguard Fiduciary Trust Co.
11.60 %
18,228,210 11.60 % 1 283 M $
BlackRock Advisors LLC
10.14 %
15,938,044 10.14 % 1 122 M $
STATE STREET CORPORATION
4.026 %
6,328,129 4.026 % 445 M $
BAMCO, Inc.
3.405 %
5,352,006 3.405 % 377 M $
Select Equity Group LP
2.900 %
4,559,173 2.900 % 321 M $
Eaton Vance Management
2.601 %
4,088,095 2.601 % 288 M $
Macquarie Investment Management Business Trust
2.550 %
4,008,958 2.550 % 282 M $
Geode Capital Management LLC
2.368 %
3,721,727 2.368 % 262 M $
LB Hercules Holdings LLC
2.349 %
3,692,675 2.349 % 260 M $
Brown Capital Management LLC
2.259 %
3,550,990 2.259 % 250 M $

Company contact information

Bio-Techne Corp.

614 McKinley Place North East

55413-2610, Minneapolis

+612 379 8854

http://www.bio-techne.com
address Bio-Techne Corporation(TECH)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Sales per Business

Sales per region

Ratings for Bio-Techne Corporation

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
63.69 USD
Average target price
80.43 USD
Spread / Average Target
+26.29%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-17.46% 10.01B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+3.13% 43.43B
LONZA GROUP AG Stock Lonza Group AG
+48.54% 41.69B
MODERNA, INC. Stock Moderna, Inc.
+8.49% 41.31B
CELLTRION, INC. Stock Celltrion, Inc.
-10.82% 27.14B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.26% 25.28B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-23.69% 18.47B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
+1.58% 12.33B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+32.83% 12.59B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.63% 11.03B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. TECH Stock
  4. Company Bio-Techne Corporation